NL-OMON37192已完成不适用
A PHASE 1, SINGLE ASCENDING DOSE, MULTIPLE ASCENDING DOSE AND SINGLE DOSE FOOD EFFECT STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF LND101001 IN HEALTHY MALE AND FEMALE SUBJECTS - LND101001 single and multiple ascending dose study
upin Ltd0 个研究点目标入组 74 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 74
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- SAD: healthy male and female subjects, MAD: healthy male subjects
- •- 18-65 yrs, inclusive
- •- BMI: 18.0-30.0 kg/m2, inclusive
- •- non-smoking
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
Evaluation of biomarkers for JAK inhibitorKCT0005706Seoul National University Hospital8
已完成
1 期
A Phase I Single-Ascending Dose and Multiple-Ascending Dose Study of RO6889450 in Healthy Japanese MaleHealthy adultsJPRN-jRCT2080224516Chugai Pharmaceutical Co., Ltd.64
未知
1 期
Phase 1/2 study of KHK7580Secondary hyperparathyroidism in patients receiving hemodialysisJPRN-jRCT2080222208Kyowa Hakko Kirin Co., Ltd.
已完成
1 期
PAT-SM6 in Patients with Recurrent In-Transit Cutaneous MelanomaRecurrent in-transit cutaneous melanomaCancer - Malignant melanomaSkin - Other skin conditionsACTRN12610000733077Patrys Limited9
已完成
1 期
Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adultsACTRN12616000846426CSL Limited56